195 related articles for article (PubMed ID: 24846067)
1. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.
Rossi M; Amodio N; Di Martino MT; Tagliaferri P; Tassone P; Cho WC
Curr Pharm Biotechnol; 2014; 15(5):459-67. PubMed ID: 24846067
[TBL] [Abstract][Full Text] [Related]
2. The potential role of miRNAs in multiple myeloma therapy.
Caracciolo D; Montesano M; Altomare E; Scionti F; Di Martino MT; Tagliaferri P; Tassone P
Expert Rev Hematol; 2018 Oct; 11(10):793-803. PubMed ID: 30148649
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs in the pathobiology of multiple myeloma.
Lionetti M; Agnelli L; Lombardi L; Tassone P; Neri A
Curr Cancer Drug Targets; 2012 Sep; 12(7):823-37. PubMed ID: 22671930
[TBL] [Abstract][Full Text] [Related]
4. miRNA deregulation in multiple myeloma.
Bi CL; Chng WJ
Chin Med J (Engl); 2011 Oct; 124(19):3164-9. PubMed ID: 22040573
[TBL] [Abstract][Full Text] [Related]
5. miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
[TBL] [Abstract][Full Text] [Related]
6. Aberrant microRNA expression in multiple myeloma.
Dimopoulos K; Gimsing P; Grønbæk K
Eur J Haematol; 2013 Aug; 91(2):95-105. PubMed ID: 23586898
[TBL] [Abstract][Full Text] [Related]
7. Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma.
Calvo KR; Landgren O; Roccaro AM; Ghobrial IM
Semin Hematol; 2011 Jan; 48(1):39-45. PubMed ID: 21232657
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment.
Raimondi L; De Luca A; Morelli E; Giavaresi G; Tagliaferri P; Tassone P; Amodio N
Biomed Res Int; 2016; 2016():6504593. PubMed ID: 26881223
[TBL] [Abstract][Full Text] [Related]
9. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.
Rossi M; Amodio N; Di Martino MT; Caracciolo D; Tagliaferri P; Tassone P
Curr Drug Targets; 2013 Sep; 14(10):1144-9. PubMed ID: 23834146
[TBL] [Abstract][Full Text] [Related]
10. Roles of miRNA dysregulation in the pathogenesis of multiple myeloma.
Chen D; Yang X; Liu M; Zhang Z; Xing E
Cancer Gene Ther; 2021 Dec; 28(12):1256-1268. PubMed ID: 33402729
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis.
Pourhanifeh MH; Mahjoubin-Tehran M; Shafiee A; Hajighadimi S; Moradizarmehri S; Mirzaei H; Asemi Z
IUBMB Life; 2020 Mar; 72(3):314-333. PubMed ID: 31828868
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation of microRNA genes in multiple myeloma.
Wong KY; Huang X; Chim CS
Carcinogenesis; 2012 Sep; 33(9):1629-38. PubMed ID: 22715154
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance.
Puła A; Robak P; Robak T
Curr Med Chem; 2021 Oct; 28(33):6753-6772. PubMed ID: 33949926
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.
Botta C; Cuce M; Caracciolo D; Fiorillo L; Tagliaferri P; Tassone P
Curr Cancer Drug Targets; 2017; 17(9):819-838. PubMed ID: 28359248
[TBL] [Abstract][Full Text] [Related]
15. The role of circulating miRNAs in multiple myeloma.
Zhang J; Xiao X; Liu J
Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-21 and multiple myeloma: small molecule and big function.
Ma J; Liu S; Wang Y
Med Oncol; 2014 Aug; 31(8):94. PubMed ID: 24981236
[TBL] [Abstract][Full Text] [Related]
17. Functional Analysis of microRNA in Multiple Myeloma.
Di Martino MT; Amodio N; Tassone P; Tagliaferri P
Methods Mol Biol; 2016; 1375():181-94. PubMed ID: 25971914
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma.
Wong KY; Chim CS
Epigenomics; 2015; 7(6):985-1001. PubMed ID: 26417914
[TBL] [Abstract][Full Text] [Related]
19. miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance.
Tavakoli Pirzaman A; Ebrahimi P; Hasanpour AH; Shakeri M; Babajani B; Pourali Ganji Z; Babaei H; Rahmati A; Hosseinzadeh R; Doostmohamadian S; Kazemi S
Technol Cancer Res Treat; 2023; 22():15330338231202391. PubMed ID: 37728167
[TBL] [Abstract][Full Text] [Related]
20. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
